Eton Pharmaceuticals Inc (ETON)vsTeva Pharma Industries Ltd ADR (TEVA)

ETON

Eton Pharmaceuticals Inc

NASDAQ

$27.40

-4.46%

HEALTHCARE · Cap: $889.70M

TEVA

Teva Pharma Industries Ltd ADR

NYSE

$34.43

-3.32%

HEALTHCARE · Cap: $40.32B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 19857% more annual revenue ($17.35B vs $86.93M). TEVA leads profitability with a 9.0% profit margin vs -1.7%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

ETON

Avoid

out of 100

Grade: F

Growth: 7.3Profit: 4.0Value: 5.0Quality: 5.0

Piotroski: 4/9Altman Z: -0.31

TEVA

Strong Buy

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0

Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ETON1 strengths · Avg: 10.0/10

Revenue GrowthGrowth

40.4%10/10

Revenue surging 40.4% year-over-year

TEVA2 strengths · Avg: 9.0/10

EPS GrowthGrowth

72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation

0.858/10

Growing faster than its price suggests

Areas to Watch

ETON4 concerns · Avg: 2.3/10

Market CapQuality

$889.70M3/10

Smaller company, higher risk/reward

Price/BookValuation

24.5x2/10

Trading at 24.5x book value

Return on EquityProfitability

-4.8%2/10

ROE of -4.8% — below average capital efficiency

EPS GrowthGrowth

-12.6%2/10

Earnings declined 12.6%

TEVA4 concerns · Avg: 3.0/10

P/E RatioValuation

25.8x4/10

Moderate valuation

Revenue GrowthGrowth

2.3%4/10

2.3% revenue growth

Free Cash FlowQuality

$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth

0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ETON

The strongest argument for ETON centers on Revenue Growth. Revenue growth of 40.4% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : ETON

The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

ETON profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.

ETON carries more volatility with a beta of 0.89 — expect wider price swings.

ETON is growing revenue faster at 40.4% — sustainability is the question.

ETON generates stronger free cash flow (7M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 29/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eton Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

ETON vs TAK ETON vs HLN ETON vs ZTS ETON vs UTHR ETON vs VTRS TEVA vs TAK TEVA vs HLN TEVA vs ZTS TEVA vs UTHR TEVA vs VTRS

Want to dig deeper into these stocks?

Full ETON Analysis →Full TEVA Analysis →